Multiple sclerosis: pharmacogenomics and personalised drug treatment

被引：0
作者：
V. Annibali
G. Ristori
S. Cannoni
S. Romano
A. Visconti
A. Ghazaryan
L. Figà Talamanca
M. Salvetti
R. Mechelli
机构：
[1] Ospedale S. Andrea,Department of Neurology and Centro Neurologico Terapia Sperimentale (CENTERS)
[2] University of Rome “La Sapienza”,undefined
来源：
Neurological Sciences | 2006年 / 27卷
关键词：
Pharmacogenomics; Multiple sclerosis; Therapy; Microarrays;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Multiple sclerosis (MS) is a disorder of the central nervous system with an inflammatory and a neurodegenerative component. We do not yet have a definitive therapy for MS. Attempts to develop new treatments are long and costly and should be paralleled by studies aimed at increasing the therapeutic index of the existing treatments, interferon β and glatiramer acetate. Pharmacogenetics and pharmacogenomics may be of use in this respect though their application may not be straightforward, particularly in MS.
引用
收藏
页码：s347 / s349
相关论文
共 50 条
[21]   TREATMENT OF MULTIPLE SCLEROSIS [J].
Bosnjak-Pasic, Marija ;
Vidrih, Branka ;
Miskov, Snjezana ;
Demarin, Vida .
ACTA CLINICA CROATICA, 2009, 48 (03) :349-353
[22]   Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research [J].
Grossman, Iris ;
Knappertz, Volker ;
Laifenfeld, Daphna ;
Ross, Colin ;
Zeskind, Ben ;
Kolitz, Sarah ;
Ladkani, David ;
Hayardeny, Liat ;
Loupe, Pippa ;
Laufer, Ralph ;
Hayden, Michael .
PROGRESS IN NEUROBIOLOGY, 2017, 152 :114-130
[23]   Advancing drug delivery systems for the treatment of multiple sclerosis [J].
Inna Tabansky ;
Mark D. Messina ;
Catherine Bangeranye ;
Jeffrey Goldstein ;
Karen M. Blitz-Shabbir ;
Suly Machado ;
Venkatesh Jeganathan ;
Paul Wright ;
Souhel Najjar ;
Yonghao Cao ;
Warren Sands ;
Derin B. Keskin ;
Joel N. H. Stern .
Immunologic Research, 2015, 63 :58-69
[24]   Advancing drug delivery systems for the treatment of multiple sclerosis [J].
Tabansky, Inna ;
Messina, Mark D. ;
Bangeranye, Catherine ;
Goldstein, Jeffrey ;
Blitz-Shabbir, Karen M. ;
Machado, Suly ;
Jeganathan, Venkatesh ;
Wright, Paul ;
Najjar, Souhel ;
Cao, Yonghao ;
Sands, Warren ;
Keskin, Derin B. ;
Stern, Joel N. H. .
IMMUNOLOGIC RESEARCH, 2015, 63 (1-3) :58-69
[25]   Multiple Sclerosis: Pathogenesis and Treatment [J].
Loma, Ingrid ;
Heyman, Rock .
CURRENT NEUROPHARMACOLOGY, 2011, 9 (03) :409-416
[26]   Natalizumab Treatment in Multiple Sclerosis [J].
Kurtuncu, Murat .
NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2011, 48 :56-60
[27]   Current treatment of multiple sclerosis [J].
Gout, O. ;
Bensa, C. ;
Assouad, R. .
REVUE DE MEDECINE INTERNE, 2010, 31 (08) :575-580
[28]   Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis (review) [J].
Boyko, A. N. ;
Gusev, E. I. .
ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) :93-99
[29]   An Investigation into the Desire for Personalised Information Provision by People with Multiple Sclerosis [J].
Qutaishat, Fadi T. ;
Probets, Steve ;
Hepworth, Mark .
BUSINESS TRANSFORMATION THROUGH INNOVATION AND KNOWLEDGE MANAGEMENT: AN ACADEMIC PERSPECTIVE, VOLS 1-2, 2010, :458-+
[30]   Treatment of multiple sclerosis fatigue with the synthetic psychoactive drug modafinil [J].
Cocco, Eleonora ;
Fadda, Paola .
EXPERIMENTAL NEUROLOGY, 2022, 347
12345